At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 29 enrolled
Drug / intervention
Erythromycin +1 moredrug
Likely dose
Erythromycin 250 mg or 500 mg three times daily for 6 weeksAI-extracted
Key inclusion· 4
- ✓Diagnosis of bulimia nervosa per DSM criteria
- ✓Illness duration greater than 1 year
- ✓Self-induces vomiting as purging behavior
- ✓Weight between 80% and 120% of ideal body weight
Key exclusion· 13
- ✕Significant medical illness
- ✕Current or lifetime history of schizophrenia, bipolar disorder, or other psychotic disorder
- ✕Moderate to severe depression (Hamilton Depression Scale score >18)
- ✕Organic mental disorder, factitious disorder, or malingering
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of Erythromycin on Binge Eating and GI Function in Bulimia Nervosa
In Brief
A Phase 2 clinical trial evaluating Erythromycin and Placebo for Bulimia Nervosa and Eating Disorders. Completed, enrolled 29 participants across 1 site.
Detailed Summary
This study will determine the effectiveness of the antibiotic erythromycin in enhancing gastrointestinal function and decreasing the frequency of binge eating in people with bulimia nervosa.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBulimia Nervosa, Eating Disorders
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH)
Timeline
Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2004
First PostedMar 2006
Primary CompletionNov 2011
TodayJul 2026
First PostedMar 17, 2006
Enrollment StartSep 1, 2004
Primary CompletionNov 1, 2011
TodayJul 2, 2026
Enrollment to primary: 7.2 yearsPosted 20.3 years ago
Interventions
Erythromycindrug
Erythromycin, 250 mg or 500 mg, three times a day for 6 weeks
Placebodrug
Placebo, 250 mg or 500 mg, three times a day for 6 weeks